Galapagos Achieves Clinical Proof-of-Mechanism Milestone in GSK Alliance

Galapagos NV

announced today that investigational medicine GLPG0778, which is part of its immuno- inflammatory alliance with GlaxoSmithKline

, has shown selective effects on a biomarker in a Phase I Proof-of-Mechanism study in healthy volunteers. The study also provided information on the safety and pharmacokinetic profile of GLPG0778.